Multiple sclerosis (MS) patients may experience severe disease exacerbation after switching from Novartis’ Gilenya (fingolimod) to Sanofi Genzyme’s Lemtrada (alemtuzumab), a case report suggests. This unexpected high disease activity ... Read more
RedHill Biopharma has received a Notice of Allowance for a new patent on RHB-104 its potential therapy for patients with relapsing-remitting multiple sclerosis (RRMS). Once granted by the United States ... Read more
Older men with multiple sclerosis (MS) have more harmful lifestyles than older women with the disease, concludes the Canadian Survey of Health, Lifestyle and Aging with Multiple Sclerosis. ... Read more
A patient satisfaction evaluation of three autoinjector devices for delivering multiple sclerosis treatments found that Bayer’s electronic autoinjector Betaconnect was the choice of 57 percent of ... Read more
According to a new clinical trial, the allergy treatment cetirizine fails to alleviate a flu-like condition that interferon-beta treatment generates in people with relapsing-remitting multiple sclerosis.
The ... Read more
The over-the-counter antioxidant lipoic acid slowed brain deterioration in patients with secondary progressive multiple sclerosis (SPMS), according to a pilot study.
An Oregon Health & Science University ... Read more
Ocrevus (ocrelizumab) significantly reduces disease activity and disability progression in patients with relapsing multiple sclerosis (MS) and primary progressive MS (PPMS), according to results of post-hoc analyses ... Read more
Members of Parliament are helping the Multiple Sclerosis Society of Canada commemorate May as MS Awareness Month. The lawmakers will be meeting with society representatives and other members of ... Read more
A modified Paleolithic diet reduced fatigue and increased the quality of life of patients with relapsing-remitting multiple sclerosis (RRMS), a study shows. The diet may also ... Read more
Pin It on Pinterest